Table 2 Relative risk and 95% confidence interval of upper gastrointestinal bleeding according to plasma half life of non‐steroidal anti‐inflammatory drugs and stratified by daily dose.
| NSAID plasma half life | Patients | Controls | Age‐adjusted RR (95% CI) | Adjusted condition RR (95% CI)* |
|---|---|---|---|---|
| All NSAID dose | ||||
| <12 H | 406 | 388 | 2.4 (2.1 to 2.8) | 4.0 (3.3 to 4.9) |
| ⩾12 H | 207 | 95 | 5.1 (4.0 to 6.5) | 9.4 (6.9 to 12.7) |
| Low‐medium daily dose | ||||
| <12 H | 250 | 275 | 2.1 (1.8 to 2.5) | 3.5 (2.8 to 4.5) |
| ⩾12 H | 58 | 41 | 3.3 (2.2 to 4.9) | 6.4 (3.9 to 10.6) |
| High daily dose | ||||
| <12 H | 156 | 113 | 3.4 (2.5 to 4.1) | 5.0 (3.6 to 6.9) |
| ⩾12 H | 149 | 54 | 6.4 (4.7 to 8.8) | 12.4 (8.1 to 18.8) |
NSAIDs, non‐steroidal anti‐inflammatory drugs.
*Adjusted for age, sex, calendar semester, ulcer history, nitrates, anticoagulants, antiplatelets, acid‐suppressing drugs, coxib and aspirin use.